Duke Medicine announced that Opeyemi Olabisi, MD, PhD, a researcher at Massachusetts General Hospital who investigates the use of patient-stem cell-derived podocytes as tools for uncovering disease mechanisms of APOL1 nephropathy, will be joining the DMPI and the Duke Division of Nephrology later this year. APOL1 nephropathy accounts for much of the excess risk of end stage kidney disease in people of recent African ancestry.
Chief of the Division of Nephrology, Dr. Myles Wolf, MD, announced the recruitment, praising Dr. Olabisi's passion for translating basic research into prevention and innovative therapy for patients at risk for or suffering from chronic kidney disease.
Welcome Dr. Olabisi to Duke and the DMPI!